Pharmaceuticals

Profusa launches its Lumee system for research, aiming to capture a piece of the $47B CRO market and revolutionize drug development with real-time data.

A new partnership aims to revolutionize chronic care by letting patients self-administer large-volume biologics safely in their own homes.

In a strategic move to enhance domestic drug production, Agno Pharma has acquired a key Oregon manufacturing site, signaling major industry consolidation.

With a new $16.5M loan, Ocular Science is poised to expand its role in compounded eye medications, meeting the needs of an aging population.

Backed by Canada's life sciences engine adMare, new biotech firm Ocythera is advancing a unique non-retinoid therapy for debilitating bone disorders.

With the appointment of agency veteran Raffi Siyahian, VaultBio aims to bridge the gap between life sciences strategy and real-world market execution.

A new partnership aims to make life-saving cancer and anti-infective drugs stable at room temperature, revolutionizing global access and sustainability.

Merck's former R&D IT head Matt Studney joins TetraScience, a move highlighting biopharma's critical pivot from fragmented data to industrial-scale AI.

International Healthcare Week 2026 will unite pharma, medtech, and labs, aiming to transform healthcare for 700 million people across Southeast Asia.

The Korean biopharma giant is leveraging its biosimilar success to fund a major push into cutting-edge cancer therapies and advanced drug platforms.

As Moelis & Co. prepares to report its 2025 results, investors are watching to see if the firm capitalized on a record year for dealmaking.

Flashpoint Therapeutics appoints an FDA-approved drug developer as CSO, a strategic move to accelerate its groundbreaking structural nanomedicine platform.

From developing neonatal ventilators to pivotal COVID vaccine research, a San Antonio institute marks 85 years on the front lines of global health.

A new alliance in healthcare marketing merges pharmaceutical expertise with provider-side insights, leveraging AI and big data to fix a fragmented system.

Adial Pharmaceuticals files a key patent to protect its personalized Alcohol Use Disorder drug, AD04, until 2045, signaling a new era for addiction medicine.

A new AI solution promises to automate a critical manufacturing step, tackling costly errors and downtime that plague the life sciences industry.

With new data showing six-month efficacy and a unique liquid formula, Galderma's Relfydess is poised to challenge established players in the neuromodulator space.

A coalition of top GOP senators and state attorneys general is urging the FDA to pull mifepristone, escalating the fight over abortion to the federal level.

AstraZeneca's acquisition of Modella AI signals a major shift, embedding advanced AI directly into its cancer research to accelerate new treatments.

With new funding from BroadOak Capital Partners, Axol Bioscience is set to expand its revolutionary iPSC-based disease models in the US market.